News

For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

8th Jul 14

Pharmaxis Update on Timing of Pre-Clinical Partnering Projects

Pharmaceutical development company Pharmaxis today provided an update on progress in securing partners for its lead drug discovery projects. This activity was announced as part of the May 2013 business plan, and the company had targeted completion of the LOXL2 partnering by mid year.

Read full media release - pdf
8th Jul 14

Communication from Financier NovaQuest

Pharmaxis advises that on July 4, 2014 it received a notice from NovaQuest Capital Management, an affiliate of NovaQuest Pharma Opportunities Fund III, L.P. (“NovaQuest”), alleging Pharmaxis has breached the Financing Agreement, dated January 30, 2013, between the Company and NovaQuest and that an event of default will occur on August 3, 2014.

The Company strongly rejects the allegation it is in breach, will contest the allegation and take all appropriate steps to ensure that NovaQuest complies fully with its obligations under the Financing Agreement.

Read full media release - pdf
30th Jun 14

Bronchitol Shortlisted for Prestigious Orphan Drug Award

Pharmaceutical development company Pharmaxis is pleased to announce that its product for cystic fibrosis, Bronchitol, has been shortlisted for the prestigious UK Prix Galien Orphan Drug Award.

Prix Galien is an internationally-recognised award, providing global recognition for the technical, scientific and clinical research skills necessary to develop innovative medicines. Moreover, it gives pharmaceutical companies the opportunity to have their products scrutinised by some of the UK medical profession’s most eminent experts, and to be assessed according to the medical, societal and economic benefits they are likely to provide.

The UK Prix Galien judging team is led by Professor Sir Michael Rawlins, President of the Royal Society of Medicine and, until 2013, founding Chairman of the National Institute of Health and Care Excellence. Professor Rawlins is joined by a panel of influential stakeholders from the UK healthcare system.

 

Read full media release - pdf